Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune...

Area of Science:

• Oncology
• Immunology
• Urology

Background:

• Bladder cancer (BC) is a common malignancy, with most cases diagnosed as non-muscle-invasive bladder cancer (NMIBC).
• Intravesical Bacillus Calmette-Guérin (BCG) is the standard adjuvant therapy for high-risk NMIBC, inducing a local immune response.
• Significant recurrence and progression rates necessitate improved treatment strategies for NMIBC.

Purpose of the Study:

• To review the biological rationale and clinical evidence for combining intravesical BCG with immune checkpoint inhibitors (ICIs) in high-risk NMIBC.
• To analyze the immunological mechanisms of BCG and the potential role of ICIs in overcoming resistance.
• To evaluate clinical trial data regarding patient populations, study design, safety, and efficacy.

Main Methods:

• Conducted a literature review of immunological mechanisms and clinical trial data.
• Analyzed studies on BCG's immune-priming effects and ICIs' role in modulating the tumor microenvironment.
• Evaluated early-phase and Phase III clinical trials for safety and efficacy in NMIBC treatment.

Main Results:

• BCG activates innate and adaptive immunity; ICIs may counter immune exhaustion.
• Early trials show variable responses, especially in BCG-unresponsive NMIBC.
• Recent Phase III data suggest upfront combination strategies do not consistently improve outcomes.

Conclusions:

• The combination of BCG and ICIs has a strong immunological basis but current clinical evidence is heterogeneous.
• The combination remains investigational, with limited data from early-phase or ongoing trials.
• Definitive conclusions require mature Phase III evidence, biomarkers, and demonstrated superiority over existing bladder-preserving therapies.